Create a free Feed Strategy account to continue reading

SHIC and FFAR announce collaboration

Organizations have jointly awarded $1.3 million to six research projects.

The Swine Health Information Center (SHIC) and the Foundation for Food & Agriculture Research (FFAR) have jointly awarded $1.3 million to six research projects aimed at enhancing the U.S. pork industry's preparedness for Japanese encephalitis virus (JEV). This proactive initiative is driven by the increasing risk of JEV introduction into the U.S., as the virus has recently spread to new regions, including Australia.

JEV Overview

  • Transmission: Spread via infected mosquito bites
  • Impact on Swine: Causes reproductive failures, abortions, stillbirths and weak piglets in breeding herds
  • U.S. Risk: As a transboundary disease, JEV poses a significant threat to swine health and production

Research Program Overview

  • Launched in February 2024, the SHIC/FFAR JEV Research Program sought proposals addressing prevention, detection, mitigation and consumer communication
  • From 26 proposals submitted by 23 institutions, six were selected based on their potential impact on U.S. pork producers
  • Projects focus on transmission, vector competence, wildlife roles, diagnostics, challenge models and vaccine development

Funded Projects and Goals

  1. Transmission and EpidemiologyPI: Brendan Cowled, Ausvet Pty Ltd

    • Study JEV transmission in Australian piggeries
    • Identify risk factors for outbreaks
  2. Competent VectorsPI: Angela Bosco-Lauth, Colorado State University

    • Evaluate JEV transmission by U.S. mosquito species
    • Assess vaccine protection against JEV in swine
  3. Role of WildlifePI: Daniel Peach, University of Georgia

    • Investigate the role of wild pigs in JEV spread to farms
  4. DiagnosticsPI: Katharine Bossart, Integrated Research Associates, LLC

    • Develop diagnostic tools, including ELISA kits, for JEV detection
  5. Challenge ModelsPI: Juergen Richt, Kansas State University

    • Create a pregnant sow model to study JEV’s effects on gestation
  6. Vaccine DevelopmentPI: Thomas Monath, Substipharm Biologics SA

    • Adapt the human JEV vaccine (IMOJEV) for use in swine

Expected Outcomes

  • Duration: Projects range from 9 to 24 months
  • Results will inform preparedness strategies, diagnostic advancements and consumer communication efforts to protect the U.S. swine herd

About SHIC and FFAR

  • SHIC: Launched in 2015, SHIC focuses on minimizing the impact of emerging swine diseases through research and communication
  • FFAR: Established in 2014, FFAR funds collaborative, impactful food and agriculture research to benefit farmers, consumers and the environment

For more details, visit Swine Health Information Center or contact Dr. Megan Niederwerder ([email protected]) or Dr. Lisa Becton ([email protected]).


Page 1 of 197
Next Page